C1 Uses
Vaccines | Dyadic International Vaccines Vaccines | Dyadic International The field of DNA vaccination is developing rapidly. Still in the experimental stages, DNA vaccines show great promise, and several types of vaccines are being tested in animals and humans. DNA vaccines have the potential to take immunization to a new technological level. DNA vaccines dispense with both the whole organism and its parts and get right down to the essentials: the microbe’s genetic material. In particular, DNA vaccines use the genes that code for those all-important antigens. Based on very preliminary experiments there are indications that the C1 technology has the potential to produce DNA vaccines at commercially viable levels, with equal or better immunogenicity. Find out more > Antibodies Antibodies are produced by the immune system in response to the presence of an antigen. Any substance capable of triggering an immune response is called an antigen. Find out more > BIOSIMILARS A biosimilar is a biologic medical product which is almost an identical copy of an original product. Biosimilars are officially approved versions of original "innovator" products. Find out more > BIOBETTERS A biobetter refers to a biologic drug that is in the same class as an existing biopharmaceutical but is not identical; it is improved over the original. Biobetters build on the success of existing biologics. Find out more >
BIOPHARMACEUTICALS Biologic drugs are some of the most expensive treatments for patients and healthcare systems. The C1 technology may help bring novel biologics, such as vaccines and antibodies, to market faster, at lower cost with improved properties. Find out more > ENZYME THERAPIES First, enzyme drugs often bind and act on their targets with affinity and specificity. Second, enzymes are catalytic and convert multiple target molecules to the desired products which accomplish therapeutic biochemistry in the body. Find out more > ANIMAL HEALTH Animal health companies and veterinary medicine academic centers are adapting human therapeutic solutions for the production of affordable animal biological drugs. Here the cost of manufacturing of biologic vaccines and antibodies is expected to play a critical role. Dyadic's C1 technology has the potential to bring such biologics to market faster, in greater volumes, at lower cost, and with new properties. Find out more >
BIOTHERAPEUTIC MANUFACTURING Biologic manufacturing processes are complex; Interacting variables such as cellular growth and metabolism, changing media conditions and feeding strategies impact cellular performance and protein quality attributes. Find out more > ENZYME CATALYSTS Enzymes can replace conventional catalysts in drug manufacturing improving efficiency & allowing reactions to take place under milder conditions offering solutions to better control stereochemistry. Find out more >
We believe there is a growing global need to find a better way to bring novel biologic drugs such as vaccines and antibodies to market faster, in greater volumes and at lower cost, and with new properties to drug developers and manufacturers and hopefully, improve access and cost to patients and the healthcare system, but most importantly saving lives.   Biologic drugs are some of the most expensive treatments, and therefore are placing an enormous burden on both patients and the healthcare systems globally.
 
Vaccines | Dyadic International Vaccines Vaccines | Dyadic International The field of DNA vaccination is developing rapidly. Still in the experimental stages, DNA vaccines show great promise, and several types of vaccines are being tested in animals and humans. DNA vaccines have the potential to take immunization to a new technological level. DNA vaccines dispense with both the whole organism and its parts and get right down to the essentials: the microbe’s genetic material. In particular, DNA vaccines use the genes that code for those all-important antigens. Based on very preliminary experiments there are indications that the C1 technology has the potential to produce DNA vaccines at commercially viable levels, with equal or better immunogenicity. Find out more > Antibodies Antibodies are produced by the immune system in response to the presence of an antigen. Any substance capable of triggering an immune response is called an antigen. Find out more >
BIOSIMILARS A biosimilar is a biologic medical product which is almost an identical copy of an original product. Biosimilars are officially approved versions of original "innovator" products. Find out more >
BIOBETTERS A biobetter refers to a biologic drug that is in the same class as an existing biopharmaceutical but is not identical; it is improved over the original. Biobetters build on the success of existing biologics. Find out more > BIOPHARMACEUTICALS Biologic drugs are some of the most expensive treatments for patients and healthcare systems. The C1 technology may help bring novel biologics, such as vaccines and antibodies, to market faster, at lower cost with improved properties. Find out more >
ENZYME THERAPIES First, enzyme drugs often bind and act on their targets with affinity and specificity. Second, enzymes are catalytic and convert multiple target molecules to the desired products which accomplish therapeutic biochemistry in the body. Find out more > ANIMAL HEALTH Animal health companies and veterinary medicine academic centers are adapting human therapeutic solutions for the production of affordable animal biological drugs. Here the cost of manufacturing of biologic vaccines and antibodies is expected to play a critical role. Dyadic's C1 technology has the potential to bring such biologics to market faster, in greater volumes, at lower cost, and with new properties. Find out more >
BIOTHERAPEUTIC MANUFACTURING Biologic manufacturing processes are complex; Interacting variables such as cellular growth and metabolism, changing media conditions and feeding strategies impact cellular performance and protein quality attributes. Find out more > ENZYME CATALYSTS Enzymes can replace conventional catalysts in drug manufacturing improving efficiency & allowing reactions to take place under milder conditions offering solutions to better control stereochemistry. Find out more >

BIOLOGIC DRUGS FOR TODAY AND TOMORROWS AGING AND GROWING PATIENT POPULATION

As the aging population grows in developed and undeveloped countries, Dyadic believes its patented and proprietary C1 technology can potentially help bring biologic drugs to market faster, in greater volumes and at lower cost to drug developers and manufacturers. This can potentially improve access and reduce costs to patients and the healthcare system.

Biopharmaceutical Markets

(1)  World Health Organization.

(2)  Human Insulin Market – Drugs Type, Brands, Delivery Devices, Applications Forecasts to 2020.

(3)  Global Market Study on Biological Drugs: North America to Witness Highest Growth By 2020.

(4)  World Biosimilars Market (follow-on-biologics) Opportunities, and Forecast, 2014-2020.

Dyadic’s global presence

History: We have developed an industrially proven expression system based on the fungus Myceliophthora thermophila, nicknamed C1.   Based on our academic and commercial collaborations, we believe experts in academia and industry regard Dyadic’s C1 expression system as among the foremost expression systems in the world.  Prior to the DuPont Transaction, the C1 technology was previously used commercially by us, and we had successfully licensed our C1 expression system, on a non-exclusive basis, to some of the world’s largest and most renowned industrial biotechnology companies such as Abengoa, BASF, Codexis, among to develop and produce industrial products from DNA such as enzymes for a wide variety of applications and industries.

On December 31, 2015 we sold substantially all the assets of our Industrial Technology business to DuPont’s Industrial Biosciences business for $75 million in cash.   DuPont has granted back to Dyadic co-exclusive rights to the C1 technology for use in human and animal pharmaceutical applications, with exclusive ability to enter into sub-license agreements in that field.  This transaction is an exceptional opportunity to unlock value and provide Dyadic operational flexibility to further develop our pharmaceutical business. We will now focus our C1 technology exclusively on the human and animal pharmaceutical markets where we believe C1 has the potential to help develop and manufacture drugs and vaccines faster and more efficiently than existing production systems.

We are optimistic about the impact that the C1 expression system may have on the development and manufacturing of biologic vaccines and drugs and that utilizing the C1 expression system may be the critical differentiator in allowing Dyadic, our collaborators and licensees to compete in these technology-driven markets. Further, we believe biologics developed without the most productive expression system will face reimbursement challenges.

Why:  The Company has long believed that the pharmaceutical field is one of the most attractive opportunities in which the C1 technology may be applied.  We believe the C1 technology platform has potential to be a safe and efficient expression system that may help speed up the development and production of biologics at flexible commercial scales. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes C1 can potentially help bring biologic drugs to market faster, in greater volumes and at lower cost, and with new properties to drug developers and manufacturers and hopefully, improve access and cost to patients and the healthcare system, but most importantly saving lives. . This can potentially improve access and reduce costs to patients and the healthcare system.

Dyadic’s C1 Technology PLATFORM

In addition, we believe the unique attributes of C1 may create attractive research, licensing, collaboration and other opportunities if C1 demonstrates operational efficiencies and reduced capital requirements for biologic drug manufacturers.

We believe in the saying that the expression system is not everything, but we believe biologics developed without the most productive expression system will face reimbursement challenges. Based on our academic and commercial collaborations, we believe experts in academia and industry regard Dyadic’s C1 Expression System as among the foremost expression systems in the world.

Proprietary & Patented Myceliophthora thermophila, commercially known as our C1 Technology: Dyadic has developed a highly productive recombinant production host that uses modern genetic recombination techniques to develop and manufacture novel enzyme and other protein products.  The C1 technology platform enables the targeted discovery, development and industrial scale manufacturing of innovative enzyme and other protein products, thereby providing customers with value-added solutions for their pressing business needs.

The use of the C1 technology platform has the potential to remove a critical bottleneck in protein development and manufacturing processes

  • Allows for rapid scaling
  • Significantly lower CapEx and OpEx
  • Potential to improve therapeutic vaccine and drug performance

Dyadic is seeking partnerships to sub-license, or partner its C1 platform technology in the vaccine, antibody and biosimilar industries.